FIG 4.

Biologics that inhibit type 2 inflammation. βc, β-chain; γc, γ-chain; ABPA, allergic bronchopulmonary aspergillosis; ADCC, antibody-dependent cellular cytotoxicity; AFR, allergic fungal rhinosinusitis; BP, bullous pemphigoid; CCL17, C-C motif chemokine ligand 17; CIU, chronic idiopathic urticaria; COPD, chronic obstructive pulmonary disorder; CRSsNP, chronic rhinosinusitis without nasal polyps; CSU, chronic spontaneous urticaria; EGPA, eosinophilic granulomatosis with polyangiitis; F_ENO, fractional exhaled nitric oxide; HES, hypereosinophilic syndrome; IL-1RαP, IL-1 receptor-α P; IL-5Rα, IL-5 receptor-α; IL-13Rα1/2, IL-13 receptor-α1/2; IL-31RA, IL-31 receptor A; IL-33R, IL-33 receptor; ILC, innate lymphoid cell; MCP-4, monocyte chemoattractant protein-4; mIgE, membrane IgE; NP, nasal polyps; OSMRβ, oncostatin-M specific receptor subunit beta; PC₂₀, provocative concentration causing a 20% drop in forced expiratory volume in 1 second from baseline; TSLPR, thymic stromal lymphopoietin receptor. Figure adapted with permission from Haddad EB et al.²²⁰